Application of the Front-Fixing Method for Numerical Modelling of Field Diffusion in Non-linear Systems

Application of a finite difference front fixing method for modelling magnetic field and associated power loss in high temperature superconductors or other strongly non-linear phenomena is considered. Advantages of the scheme are discussed and implementation problems highlighted. Particular attention is paid to conservation properties of the algorithm and accurate solutions close to the transition boundaries. The algorithm is tested using a well-known solution of the spherical diffusion problem with complex conditions at the moving interface

Probability of improvement methods for constrained multi-objective optimization

This paper shows how the simultaneous consideration of multiple Kriging models can lead to useful metrics for the selection of design vectors in constrained multiobjective optimization. The savings in computational cost with such methods make them particularly useful for optimal electromagnetic design

A hybrid GA–PS–SQP method to solve power system valve-point economic dispatch problems

This study presents a new approach based on a hybrid algorithm consisting of Genetic Algorithm (GA), Pattern Search (PS) and Sequential Quadratic Programming (SQP) techniques to solve the well-known power system Economic dispatch problem (ED). GA is the main optimizer of the algorithm, whereas PS and SQP are used to fine tune the results of GA to increase confidence in the solution. For illustrative purposes, the algorithm has been applied to various test systems to assess its effectiveness. Furthermore, convergence characteristics and robustness of the proposed method have been explored through comparison with results reported in literature. The outcome is very encouraging and suggests that the hybrid GA–PS–SQP algorithm is very efficient in solving power system economic dispatch problem

Equivalent Permeability of Step-Lap Joints of Transformer Cores: Computational and Experimental Considerations

The paper develops an efficient computational method for establishing equivalent characteristics of magnetic joints of transformer cores, with special emphasis on step-lap design. By introducing an equivalent material, the method allows the real three-dimensional structure of the laminated thin sheets to be treated computationally as a two-dimensional problem and enables comparative analysis of designs. The characteristics of the equivalent material are established by minimizing the magnetic energy of the system. To verify the proposed approach, a series of experiments have been conducted. First, the anisotropic characteristics of the step-lap were established, and then space components of the flux density at specified positions measured. This enabled detailed analysis of the flux distribution in the step-lap region, in particular the way in which the flux travels between the laminations close to the air-gap steps. Encouraging correlation between the homogenized 2-D model and experiment has been observed

Robust Global Optimization of Electromagnetic Designs Utilizing Gradient Indices and Kriging

Since uncertainties in design variables are inevitable an optimal solution must consider the robustness of the design. A methodology based on the use of first-order and second-order gradient indices is proposed introducing the notion of gradient sensitivity. A kriging method assisted by algorithms exploring the concept of rewards is utilized to facilitate function predictions for the robust optimization process. The performance of the proposed algorithms is assessed through a series of numerical experiments and the TEAM Workshop Problem 22

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)